Glenmark Pharmaceuticals Q3 Results
- BSE: 532296
- NSE: GLENMARK
- ISIN: INE935A01035
- Sector: Biotechnology & Drugs
BSE
2,166.65
-14.80 (-0.68%)
-14.80 (-0.68%)Volume45.44 K
Updated: Fri 5 Jun, 2026 | 15:25:38
NSE
2,166.20-14.40 (-0.66%)
-14.40 (-0.66%)Volume5.13 L
Updated: Fri 5 Jun, 2026 | 15:50:17
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q3 Results Highlights
Quarter ended Dec 25
Note: Comparison is on QoQ basis
Quarterly - Glenmark Pharmaceuticals Q3 Results
*All figures in crores except per share values
| Fiscal Period | Dec 25 | Sep 24 | QoQ Comp | Dec 23 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 3,369.65 | 2,952.16 | -35.37% | 2,939.15 | 15.79% |
| Depreciation/ Amortization | 154.45 | 120.28 | 9.38% | 147.08 | 25.83% |
| Operating Income | 530.97 | 481.63 | -36.28% | -,432.45 | 11.20% |
| Net Income | 403.21 | 354.21 | -33.94% | -,351.37 | 15.88% |
| Other Operating Expenses Total | 894.37 | 975.24 | -33.08% | 930.06 | -2.21% |
| Net Income Before Taxes | 534.00 | 472.57 | -44.80% | -,521.38 | 17.02% |
| Total Revenue | 3,900.62 | 3,433.80 | -35.49% | 2,506.70 | 15.15% |
| Selling/ General/ Admin Expenses Total | 841.40 | 786.56 | -22.54% | 753.04 | 6.71% |
| Diluted Normalized EPS | 19.21 | 12.55 | -63.47% | -14.89 | 55.80% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.